Today was a quiet day on the money side. The main psychedelic company stocks barely budged — Compass down about 2 percent, atai flat, Numinus and MindMed each off a fraction of a percent. That kind of small drift is normal noise, not a signal that anything is wrong. No new deal, no new government decision, no big trial result landed today. The freshest real thread is smaller: a proposed law called the MARA Act — a bill to loosen federal restrictions on psychedelics like psilocybin, the active ingredient in magic mushrooms — was recently filed in Congress, and an early, open study testing psilocybin in veterans is now circulating among people who want change. In an "open study," everyone knows they're getting the real drug, which makes the results promising but not yet proof.
Beneath the surface, watch what's actually happening: raw data is being turned into political fuel. A small veterans study on its own doesn't change medicine. But veteran suffering is one of the most powerful arguments in American politics, and advocates know it. The likely path over the next couple of months isn't a dramatic breakthrough — it's a slow assembly. The bill gathers more supporters. Veterans groups start citing the study in their campaigns. The story gets repeated in congressional statements. None of that legalizes anything this year. But it builds the foundation that later approvals stand on. The realistic, hopeful read is this: momentum is compounding, quietly, in the right direction — even on a day when nothing looks like it moved.
There's a second, less glamorous truth worth naming. The fight that actually decides whether ordinary patients can afford these treatments may not be about psilocybin at all — not yet. It's about ketamine and its cousin esketamine, sold as the nasal spray Spravato, which are already legal and already used for hard-to-treat depression. Whether insurance covers them, and at what price, sets the pattern everything else will follow. The future is being written in coverage rules right now, while the headlines look elsewhere.
For the real people inside this story — the veteran who has tried every approved medicine and still wakes up in the dark, the spouse who has learned to hope carefully — today offers something modest but honest. Their story is becoming evidence. The pilot they may have volunteered for, or read about, is turning into a name a lawmaker will say out loud. That is how change actually arrives: not in one thunderclap, but in a paper trail that slowly becomes impossible to ignore. Their pain is being converted into pressure, and pressure is what moves a system that would otherwise stand still.
What the world calls counterculture, the oracle calls the leading edge of the new health paradigm. The threads forming today will be tomorrow's standard of care.
The intelligence that created you is still creating.
72%
A private deal memo won't budge psychedelic stock prices in August
Two private companies signed a letter of intent (a non-binding agreement to potentially work together), but because neither company trades on a stock exchange, this news gives public investors nothing concrete to act on. Stock prices for publicly traded psychedelic companies like CMPS and MMED are driven by hard data — trial results, acquisitions — not private paperwork between outside firms. This prediction says none of the major listed psychedelic stocks will jump or drop more than 3% on any single day because of this deal memo.
→ A private business memo between two unlisted companies almost never moves stock prices, and this one is very likely to be no exception. (Confidence: 72%)
Resolves: 2026-08-31 · Global
MARKETS
the precise call ▾
The Rose Hill/Control Z LOI produces no measurable listed-equity move (>3%) in any named psychedelic ticker through August.. Private LOIs between non-listed entities do not create public catalysts; institutional capital ignores them. Specific to today's LOI news and falsifiable against price data. || RESOLUTION RULE: YES if no publicly listed psychedelic-sector ticker (CMPS, MMED, ATAI, CYBN, GHRS) shows a single-day clos
70%
Two key psychedelic stocks will likely stay flat through August
CMPS and MMED are two companies developing psychedelic medicines that trade on the NASDAQ stock exchange. Without a major announcement — like final results from a large clinical trial or a buyout deal — there's no strong reason for their stock prices to swing sharply in either direction. This prediction says both stocks will end August within 8% of where they started, as long as no game-changing news drops.
→ Without a big trial result or acquisition, both stocks are likely to drift sideways through August — nothing dramatic is expected. (Confidence: 70%)
Resolves: 2026-08-31 · Global
MARKETS
the precise call ▾
CMPS and MMED remain within ±8% of today's close through August absent a Phase 3 readout or M&A event.. Nothing in today's tape (LOIs, academic pilots) is a de-risking catalyst; institutions wait for topline data or deals. Ticker-anchored, near-term, and clearly falsifiable. || RESOLUTION RULE: YES if, at market close 2026-08-31, both CMPS (NASDAQ) and MMED (NASDAQ) close within ±8% of their 2026-08-0
66%
A psychedelic medicine bill will get more supporters but no vote before fall
The MARA Act (Medical Alternatives to Reduce Addiction Act) is a proposed US law that would expand access to psychedelic treatments, especially for veterans. More members of Congress are expected to sign on as supporters, but the bill is very unlikely to actually get a formal committee hearing or vote before Congress goes on its fall recess. This is a familiar pattern — bills gain names on a list but stall before any real action.
→ The MARA Act is gaining supporters on paper but is very unlikely to get an actual hearing or vote before Congress breaks for fall. (Confidence: 66%)
Resolves: 2026-10-15 · USA
LEGISLATION
the precise call ▾
MARA Act gains additional cosponsors but receives no committee markup or hearing before fall recess.. Double filing builds a cosponsor list, but leadership won't schedule contentious drug legislation pre-election. This pattern has held repeatedly. Anchored to today's MARA double-filing catalyst. || RESOLUTION RULE: YES if, per congress.gov MARA Act bill page, the cosponsor count is higher than its c
66%
Veterans psychedelic pilot results will show up in Congress within 8 weeks
A pilot program giving psilocybin (the active compound in magic mushrooms) to veterans produced results that advocates and lawmakers find politically powerful. Within the next eight weeks — by late September 2026 — at least one member of Congress or a formal advocacy group is expected to publicly reference this pilot in a statement, speech, or official filing. Veterans' health outcomes resonate strongly with politicians across party lines.
→ Positive results from the veterans psilocybin pilot are very likely to get name-dropped in Congress or an official advocacy document before late September 2026. (Confidence: 66%)
Resolves: 2026-09-27 · USA
LEGISLATION
the precise call ▾
The veterans psilocybin pilot is cited in at least one congressional statement or VA-access advocacy filing within 8 weeks.. Veteran outcome data is politically potent and advocates amplify positive signals quickly. MARA momentum gives it a legislative venue. Specific, near-term, and falsifiable. || RESOLUTION RULE: YES if the veterans psilocybin pilot is explicitly referenced in a congressional floor statement, Congressi
63%
A major veterans group will back psychedelic medicine access within 6 weeks
Large veterans service organizations — groups like the VFW (Veterans of Foreign Wars), the American Legion, IAVA (Iraq and Afghanistan Veterans of America), or the DAV (Disabled American Veterans) — have millions of members and enormous political influence. Within six weeks, at least one of these groups is expected to publicly endorse the MARA Act or specifically cite the veterans psilocybin pilot in a campaign pushing for broader access. When both data and a live bill exist, these organizations tend to move.
→ There's a decent chance a major veterans organization publicly backs psychedelic medicine access before mid-September 2026 — veterans' data plus an active bill is exactly what moves these groups. (Confidence: 63%)
Resolves: 2026-09-13 · USA
LEGISLATION
the precise call ▾
At least one veterans service organization publicly endorses MARA or cites the psilocybin pilot in an access campaign within 6 weeks.. The veterans pilot gives advocates concrete data; MARA's double filing shows sponsors want cover. VSOs mobilize when there is both data and a bill to rally behind — a near-term, checkable event tied to today's filing. || RESOLUTION RULE: YES if a named US veterans service organization (e.g., VFW, Am